Healthcare >> CEO Interviews >> April 28, 2003
IAN MCBEATH is President and Chief Executive Officer of Inflazyme
Pharmaceuticals Ltd, since May 1998. Prior to that he was a
founding Director and Chief Executive for BioVex Limited, a UK-
based company developing gene therapy products. Mr. McBeath has
almost 30 years' experience at senior levels in the biotechnology
and pharmaceutical industries in the US and Europe. In the
pharmaceutical industry he has held senior executive positions
with three major 'blue chip' companies: Beecham (now
GlaxoSmithKline), Johnson & Johnson, and ICI Pharmaceuticals (now
AstraZeneca). He has previously been President and CEO of two UK
biopharmaceutical companies and established and ran the European
operations for a San Diego-based company. He is currently a
member of the Premier's Technology Council, a committee set up to
advise and assist the Premier of British Columbia on growing high
technology industries. He is also past Chairman of BC Biotech,
the Biotechnology Trade Association for British Columbia. His
industry experience extends from early stage product development
through to international marketing. Mr. McBeath has extensive
experience building and financing early stage biopharmaceutical
companies. Profile
company's technology platforms, etc.?
Mr. McBeath: Inflazyme is focused on inflammatory diseases. Our
main technology is built
